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Oxidative stress (OS) is thought to play an important role in the pharmacological and toxic effects of various drugs of abuse. Herein
we review the literature on the mechanisms responsible for the cardiovascular and hepatic toxicity of cocaine with special focus
on OS-related mechanisms. We also review the preclinical and clinical literature concerning the putative therapeutic effects of
OS modulators (such as N-acetylcysteine, superoxide dismutase mimetics, nitroxides and nitrones, NADPH oxidase inhibitors,
xanthine oxidase inhibitors, and mitochondriotropic antioxidants) for the treatment of cocaine toxicity. We conclude that available
OS modulators do not appear to have clinical efficacy.
1. Introduction
Oxidative stress (OS) can be defined as an unbalance between
the production of reactive oxygen and nitrogen species
(ROS and RNS) and the compensatory response of physio-
logical antioxidant mechanisms. The main ROS are super-
oxide (O
2
∙−), hydrogen peroxide (H
2
O
2
), hydroxyl (∙OH),
hydroperoxyl (HO
2
∙), peroxyl (RO
2
∙), alkoxyl (RO∙), singlet
oxygen (1O
2
), hypochlorous acid (HOCl), and ozone (O
3
)
while the main RNS are nitric oxide (∙NO), nitrogen diox-
ide (∙NO
2
), peroxynitrite (ONOO−), nitrous acid (HNO
2
),
dinitrogen tetroxide (N
2
O
4
), dinitrogen trioxide (N
2
O
3
), and
nitronium cation (NO2+). The most important sources of
ROS and RNS are represented by enzymatic reactions local-
ized in the mitochondria, the microsomes (cytochrome P450
enzymes), the cytosol such as xanthine oxidase (XO), and
the membrane-associated protein complex with its cytosolic
subunits NADPH oxidase (Nox). The production of ROS in
the phagocytes depends on the activity of peroxidases such as
myeloperoxidase and eosinophil peroxidase.
It has been suggested that OS plays an important role
in the physiopathology of various apparatuses and organs
including the cardiovascular system (ischemia and reperfu-
sion injury, heart failure, atherosclerosis, hypertension, etc.)
and the liver (acute and chronic damage) [1, 2]. There is also
evidence of significant involvement of OS in the pharmaco-
logical and toxic effects of drugs of abuse and particularly of
psychostimulants such as cocaine andmethamphetamine [3].
The level of OS in the aforementioned conditions can be
measured by a number of biomarkers, including H
2
O
2
, NO
derivatives (nitrite, nitrate, and S-nitrosothiols), isoprostanes
(deriving from the peroxidation of arachidonic acid), MDA
and other thiobarbituric acid reactive substances (TBARS),
4-hydroxynonenal (4-HNE), acrolein, thiol/disulfide ratio,
oxidation products of DNA (8-hydroxy-2-deoxyguanosine,
8-OH-G) and RNA (8-hydroxyguanosine, 8-OHD), and
nitrotyrosine. It is of note that, in several studies, cocaine-
induced OS was evaluated by the measurement of TBARS
[4–9] which is considered inferior to other methods for lipid
peroxidation like the evaluation of F2-isoprostanes [10].
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In the present paper, we review the literature concerning
the cardiovascular and hepatic toxicity of cocainewith special
attention to the role of OS and the evidences about the
possiblemodulators of OSwhich could have beneficial effects
in cocaine users.
2. Cardiovascular Toxicity of Cocaine
The earliest case reports of cardiovascular toxicity attributed
to cocaine date from the 1980s [11–13]. Cocaine abuse is asso-
ciated with both acute and chronic cardiovascular toxicity
[14–16], includingmyocardial ischemia [13, 17] and infarction
[18], arrhythmias [19], and cardiomyopathy [20–22]. Recent
epidemiological data indicate that cocaine is responsible for
a sizeable proportion of emergency department visits and
of sudden deaths [23, 24]. Data from 19 European countries
indicated more than 500 cocaine-related deaths in 2012 [25].
Approximately 5% to 10% of emergency department visits in
the United States have been attributed to cocaine-acute tox-
icity, chest pain being the most common symptom [15]. The
upward trend in cocaine-related chest pain and myocardial
infarction cases has induced the America Heart Association
to draft diagnostic and therapeutic guidelines [26]. Data
from the relative National Cardiovascular Data Registry
was recently published [27]. Histopathological studies have
shown that cocaine can precipitate myocardial ischemia in
the presence of coronary artery occlusion [28] as well as
of normal coronary arteries [29]. A recent review [23] of
49 cocaine-related deaths identified coronary atherosclerosis,
ventricular hypertrophy, cardiomegaly,myocarditis, and con-
traction band necrosis in almost a third of cases.
The pathogenesis bases of cocaine-induced cardiovascu-
lar toxicity [14, 30, 31] have been studied in detail [32, 33].
Cardiovascular cocaine toxicity can be related to its patho-
physiological effects on the sinoatrial node,myocardium, and
vasculature, including the coronary district.
2.1. Pathogenetic Mechanisms of the Cardiac Toxicity of
Cocaine. Cocaine can damage the heart through a variety
of mechanisms that have been elucidated only in part. In
the first place, cocaine has a direct cardiotoxic effect, due its
ability to block voltage-dependent K+ and Na++ channels in
the sinoatrial node and the myocardium, leading to reduced
contractility and to prolongation of the QT interval and the
QRS complex. It has been proposed that these two effects
may produce acute myocardial ischemia and infarction also
in absence of long-term cocaine abuse, of abnormalities in the
coronary arteries, and of other risk factors [34, 35].
Cocaine can exert its toxic effect on the heart also
indirectly, through the actions of catecholamines, and in
particular of norepinephrine. Indeed, cocaine is known
to block the reuptake of catecholamines by binding the
transporters for dopamine (DAT) and norepinephrine (NET)
[36]. Increased norepinephrine levels in the terminals of the
sympathetic nervous system lead to activation of adrenergic
receptors. Activation of 𝛽1 adrenergic receptors located on
the cells of the sinoatrial node and of the myocardium results
in increased heart rate and contractility. Activation of 𝛼1
receptors located on the smooth muscle cells of blood vessels
leads to vasoconstriction and increased blood pressure.
Increased heart rate, heart contractility, and blood pressure
may lead to an acute imbalance in oxygen supply/demand
[37, 38]. Oxygen deficiency can be further exacerbated by
the reduction in blood supply to myocardium produced
by 𝛼1-mediated constriction of coronary arteries [13]. In
turn, oxygen deficiency may lead to myocardial infarction.
Furthermore, the combination of the direct toxic effect of
cocaine and those of norepinephrine may lead to complex
arrhythmia [39].
In addition to producing oxygen imbalance, cate-
cholamines may damage the myocardium via at least three
additional pathogenetic mechanisms [30, 40]. First cate-
cholamines can promote cation translocation from the vas-
cular space to intracellular compartment [41] thus reducing
serum K+ [42] and Mg 2+ [43]. Concurrent hypokalaemia
and hypomagnesaemia may lead, given the pivotal role of
these cations in activity of the Na+/K+-ATPase pump [44], to
further cation dyshomeostasis, which in turn may contribute
to apoptosis and necrosis of cardiomyocytes. Moreover, this
mechanism [45], adding to the direct arrhythmogenic effects
of cocaine described above, may facilitate the development
of arrhythmias such as atrial fibrillation and ventricular
tachycardia.
A second pathway responsible for cardiotoxicity is
related, as first hypothesized by Fleckenstein and Coworkers
in 1974 [46], to catecholamines-induced calcium overload in
cytosol and mitochondria of cardiomyocytes [41]. Indeed,
stimulation of 𝛽-adrenergic receptors leads to activation of
protein kinase A (PKA) and increased Ca2+ levels in the
cytosol. This leads to phosphorylation of Ca2+-protein sub-
strates, including phospholamban, L-type calcium channel,
ryanodine receptor, cardiac troponin I, and myosin-binding
protein C [47, 48]. Increased cytosolic Ca2+ triggers the
release of Ca2+ in the mitochondria. The mitochondrial role
in physiological intracellular Ca2+ homeostasis as well as
in necrosis and apoptosis signaling is well demonstrated
[49]. Mitochondrial Ca2+ overload impairs respiration and
ATP production and produces change in permeability of the
mitochondrial membrane (eventually leading to its rupture),
which represents critical events for the further structural
degeneration of cardiomyocytes [50].
Moreover Ca2+ overload (as well as ROS mitochondrial
production, see below) is responsible for themassive opening
of mitochondria Permeability Transition Pores (mPTP) [51]
resulting in further dysfunctional and structural degenera-
tion of these organelles.
An indirect cardiotoxic effect of catecholamines may
derive from action of their oxidation products, the amino-
chromes. Notably, excessive level of circulating catechol-
amines (and consequent saturation of the monoaminooxi-
dase and catechol-o-methyl transferase systems) may
cause the increased formation of adrenochrome (obtained
by oxidation of adrenaline) [40, 52] of 5,6-dihydroxy-1-
methylindole and of adrenochrome alkaline rearrangement
product adrenolutin. In the heart the enzyme cytochrome c
oxidase has been associated with adrenochrome formation
[52].
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Experimental studies investigating the relationship
between aminochromes and cardiotoxicity [52, 53] demon-
strated a direct toxic effect on cardiomyocytes: disturbances
in cellular Ca2+ homeostasis and a perturbation of oxidative
phosphorylation have been reported. Accordingly, increased
levels of adrenolutin were observed in death-associated
heart failure [54]. Moreover, aminochromes are known to
induce redox cycling with consequent generation of ROS
(see below).
More recently, OS and generation of ROS have been iden-
tified as one of the most important mechanisms of cocaine-
induced cardiomyocyte toxicity [6, 30, 31, 55, 56]. Increased
expression iNOS and decreased levels of myocardial SOD
and catalase were found in the cardiomyocytes of patients
with dilated cardiomyopathy related to chronic cocaine abuse
[20]. Indeed, ROS formation has been thought to be related
to cocaine-induced catecholamine release [56]: 𝛼
1
and 𝛽
receptors stimulation, as well as enzymatic and nonenzymatic
degradation of catecholamines, lead to intracellular ROS
formation.
2.1.1. 𝛼
1
-Adrenoceptors Stimulation and Production of ROS.
In the plasma membranes of cardiac cells, 𝛼
1
-adrenoceptors
stimulation increases the activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases [57], an electron
donor which in turn produces the superoxide anion radical
O
2
∙− formation [56, 58]. The role of NADPH-driven super-
oxide production in cocaine induced cardiac dysfunction is
well recognized [59]. Indeed, the family of Nox enzymes is
considered the major sources of ROS in the cardiovascular
system [58, 60]: the proteins of the Nox family produce O
2
∙−
by transferring an electron from NADPH (or NADH) to O
2
.
It is believed that Nox1, Nox2, andNox4 are expressed signifi-
cantly in the vascular system [61, 62] while experimental data
in cardiomyocytes had demonstrated that the Nox subunit
Nox1, but notNox2 orNox4, is implicated in norepinephrine-
induced Nox-generated ROS [63]. Inhibition of Nox activity
by apocynin prevented the increase in ROS production
and cardiac dysfunction induced by chronic administration
of cocaine in vivo in rats [64]. Moreover, Nox activity is
associated with other ROS-inducing enzymatic sources such
as xanthine oxidoreductase (XOR): a fundamental role of XO
was confirmed in an in vivo experimental model of cocaine-
induced diastolic dysfunction [65], in which treatment with
XO-inhibitor allopurinol prevented the cocaine-increase in
mitochondrial ROS levels.
2.1.2. 𝛽-Adrenergic Receptors Stimulation and Production
of ROS. As discussed above, 𝛽-adrenergic receptors (𝛽-
AR) stimulation activates a GTP-binding protein S, which
stimulates adenylyl cyclase (AC) to produce cAMP, which
in turn activates PKA. It has been demonstrated that 𝛽-
AR stimulation may contribute to mitochondrial ROS pro-
duction in cardiomyocytes: indeed the 𝛽-adrenergic ago-
nist isoproterenol (ISO) increased, in a concentration- and
cAMP-protein kinase A-dependent manner, mitochondrial
O
2
∙− production in freshly isolated mouse cardiomyocytes
and induced a twofold increase of MDA protein adducts
relative to controls in perfused hearts [66]. Accordingly,
in vivo administration of mitochondria-targeted antioxidant
MitoQ had shown to prevent left ventricular (LV) diastolic
dysfunction (characterized by an increase in the index of LV
relaxation, in LV end-diastolic pressure-volume relation, and
in LV end-diastolic pressure) induced in rats treated with
cocaine for 7 days [67]. Beta-AR stimulation induced both
cAMP [68] and PKA increase both in bovine [69] and in rat
[68, 70] cardiomyocytes mitochondria.
Experimental data in mouse cardiomyocytes [66] have
demonstrated that 𝛽-AR exposure to agonist ISO leads to an
increase in ROS, suggesting ROS production as a direct con-
sequence of activation of the cAMP-PKA signaling pathway
in mitochondria. Importantly, the increase in mitochondrial
ROS production appeared to be Ca2+-independent, since a
selective increase of the amplitude of Ca2+ transient did not
increase ROS production [66].
𝛽-AR stimulation is also implicated in the impairment of
antioxidant system. Indeed, significant reduction in CuZn-
SOD enzyme activity has been found in hearts from ISO-
treated rats as well as in ISO-stimulated isolated cardiomy-
ocytes [71]. Moreover, a reduction in manganese-SOD (Mn-
SOD) expression induced by chronic ISO was more recently
found in type 5 AC (1 of 2 major AC isoforms in heart)
transgenic mice [72].
2.1.3. OS from Catecholamines Metabolites (Aminochro-
manes). As mentioned above, when the enzymatic catab-
olism of catecholamines is not sufficient, they can undergo
chemical oxidation causing additional OS [40]. The impli-
cation of aminochromanes in the pathogenesis of cardiac
diseases [53, 73] is also well recognized.
Formation of superoxide anion O
2
∙− (due to an oxida-
tion pathway that involves the formation of highly reactive
intermediaries o-semiquinones and o-quinones) [74] has
been observed in both in vivo [75] and in vitro models [74,
76]. The superoxide anion O
2
∙− can cause the oxidation of
epinephrine [52, 77, 78] and of metal ions copper [79] and
iron [77], enhancing the oxidation of catecholamines. Thus,
iron chelation can protect against the cardiotoxicity induced
by the metabolites of catecholamines: an in vitro study in rat
ventricular cardiomyoblast assessing the potential cardiopro-
tective effects of some chelating agents had suggested further
investigation in vivo animal models [80].
Catecholamines metabolites can also reduce antioxidant
defences by decreasing the levels of reduced glutathione
(GSH) and increasing the oxidized glutathione (GSSG) con-
tent as observed in adrenaline-treated isolated rat cardiomy-
ocytes [74, 79].
2.2. Pathogenetic Mechanisms of Cocaine Vascular Toxicity
2.2.1. Cocaine Effect on Vascular Smooth Muscle Cells. Co-
caine sympathomimetic activity and consequent agonist
action at 𝛼
1
adrenergic receptors (𝛼
1
-AR) in vascular smooth
muscle cells cause contraction in the vascular system. The
activation of these receptors leads in fact to the formation of
inositol triphosphate and diacylglycerol (via phospholipase
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C), which in turn cause an increase in Ca2+ entry and in
release from Ca2+ stores in smooth muscle cells [81]. Despite
the different contribution of each 𝛼
1
-AR subtype [82, 83] in
the regulation of contraction in different vascular districts,
the net result of 𝛼
1
-AR stimulation is represented by an acute
increase in blood pressure.
2.2.2. Cocaine Effect on Endothelial Cells. A further contribu-
tion in the pathogenesis of cocaine-induced vasoconstriction
is due to its acute and chronic effect on endothelial cells func-
tion [84]. An impairment in endothelium-dependent vasore-
laxation, assessed as a decrease in forearm blood flow in
response to intraarterial acetylcholine and nitroprusside, was
found in long-term users of cocaine [85]. Accordingly exper-
imental studies [86, 87] demonstrated a cocaine-induced
endothelial dysfunction with a decrease in NO release and
in the constitutive enzyme NO-synthase (eNOS) content, as
well as an increase in endothelin-1 (ET-1) production and ET-
1 receptor type-A (ETAR) protein expression [84]. Increased
number of circulating endothelial cells (CECs) indicat-
ing endothelial dysfunction was recently demonstrated in
cocaine abusers [88]. Furthermore, enhancement of cocaine-
induced vasoconstriction was observed after N(G)-nitro-L-
arginine methyl ester-induced inhibition of NO synthesis in
vitro [89].
Concomitant decrease in NO-induced vasodilatation
and ET-1-induced vasoconstriction may enhance 𝛼
1
-AR-
mediated vasoconstriction. It has been suggested that inhibi-
tion of eNOS expressionmay partially derive from high levels
of ET-1 through a PKC-mediated pathway in endothelial
cells [90] and/or through ET-1 receptor type-A (ETAR)
stimulation, which in turn can increase ROS production [91,
92].
Chronic cocaine exposure and consequent endothelial
dysfunction may precipitate early atherosclerosis [93] and
the persistence of endothelial cell damage beyond its acute
effect on the blood vessels can further increase cardiovascular
risk in cocaine abusers [88, 94]. Since that ET-1 increase
was significantly associated with atherosclerotic lesion [95], it
may be argued that it plays a fundamental role in the cocaine-
induced vasoconstriction at sites of significant stenosis [96].
Although discrepant results were also reported [97],
probably due to methodological differences, there is some
evidence indicating that cocaine may exert an inhibitory
effect on the production of prostacyclin (PGI
2
) by endothelial
cells [98, 99]. Since the release of both vasodilatatory PGI
2
and NO may result from stimulation of ET-1 receptor type-
B
1
(ETB
1
) receptors on endothelial cells, it is possible that
the inhibitory effect of cocaine on NO release also extends
to PGI
2
release [100].
Another important factor that can contribute to cocaine
prothrombotic action is its direct action on endothelial cells
secretion of vonWillebrand factor (VWF). Indeed, a recent in
vitro study [101] demonstrated that cocaine and its metabo-
lites induced VWF secretion in a concentration-dependent
manner from three endothelial cell types (human umbilical
vein, brain microvasculature coronary artery endothelial
cells).
2.2.3. Cocaine Effect on Platelet Function. Whereas both
experimental and clinical data agree on the fact that cocaine
can affect endothelial function, leading to vasoconstriction,
there is conflicting evidence about the direct effect of cocaine
on platelets. Increased platelet activation was observed in
vitro in rabbit platelet-rich plasma (PRP), preincubated with
cocaine hydrochloride [102] as well as in vivo in dogs treated
with intravenous cocaine [103]. The findings obtained with
human platelets in vitro are less consistent. At concentrations
comparable to the systemic concentrations produced by
lethal doses, cocaine decreased platelet aggregation induced
by agonists in PRP obtained from healthy human subjects
[104]. In contrast, two in vitro studies conducted with cocaine
concentrations comparable to the systemic concentrations
associated with the “high” showed increased platelet activa-
tion in whole blood preparations [105, 106], whereas other
studies found no effect of cocaine [107]. Finally, increased
platelet expression of surface P-selectin was found in blood
samples from chronic cocaine users [107]. It is possible
that these discrepancies were due to differences in substrate
(animal versus human platelets), in model (in vitro versus in
vivo), in methodology (whole blood versus PRP), and in the
concentrations of cocaine used.
In vivo studies in healthy subjects [108] and in chronic
cocaine user [109], although not univocally [110], gave evi-
dence of activation of platelets, assessed by increase of P-
selectin expression [109] and of soluble CD40L, a transmem-
brane molecule mainly expressed by activated platelets [111].
Due to physiological interaction of platelets with vascular
endothelium and circulating blood cells such leukocytes, it
may be argued that an indirect, rather than a direct, mecha-
nism of action is involved in the cocaine platelets activation.
Indeed, the above mentioned cocaine-induced vasospasm,
consequent increase in shear stress, and endothelial dys-
function may induce a platelet activation, as demonstrated
by release of constituents of their 𝛼-granules [106] and of
thromboxane A2 [99]. A further contribution may derive
from VWF interaction with the platelet receptor GPIb and
their subsequent activation [108].
2.2.4. OS and Cocaine-Induced Endothelial Toxicity. Besides
cardiomyocytes, also endothelial cells (ECs)may releaseROS,
mainly due to its presence of enzymes such as XO, NOS,
mitochondrial MAO, and NAPDH oxidase. Some data in
literature indicate a direct or an indirect cocaine action
on endothelial cells, both on enzymes expression and on
mitochondrial function.
2.2.5. XOandProduction of ROS. In bovine aortic endothelial
cells, it has been observed that shear stress induced an
enhancement of xanthine-dependent O
2
∙− production [112],
associated with a decrease in xanthine dehydrogenase (XDH)
protein. Furthermore, inhibition of the Nox decreased XO
levels and prevented the increase of O
2
∙−, highlighting the
central role of Nox in modulating endothelial production
of ROS. It may be suggested that vasoconstriction effect
of cocaine and consequent blood shear stress may trigger
endothelial ROS production via Nox/XO enzyme.
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In agreement with this hypothesis, cocaine-induced car-
diac dysfunction (alteration of cardiac output and stroke
volume) was found to be associated with increased Nox
and XOR activity in vivo study in rats [64]. Furthermore,
apocynin or allopurinol treatment inhibited the cocaine-
induced cardiac alteration and the myocardial production
of O
2
∙− confirming the role that Nox-derived ROS play in
modulating ROS production by XO [64].
2.2.6. Nitric Oxide Synthase and Production of ROS. As
mentioned above, cocaine-induced decrease in endothelial
NO release and in the constitutive enzyme eNOS content
has been observed [84]. A contribution to this cocaine
endothelial toxic effect may derive from its increasing action
in Nox, which in turn (besides the increase in O
2
∙−) may
induce oxidation of tetrahydrobiopterin, a cofactor of NO
synthase: as a consequence eNOS uncoupling leads to the
observed reduction in NO synthesis and to an enhancement
in O
2
∙− [113].
2.2.7. ROS in Endothelial Mitochondria. Besides the well-
recognized energy-producing activity, notably mitochon-
dria are the major source of cellular reactive oxygen [114]
both in cardiomyocytes and in EC [40, 115]. An impor-
tant role of endothelial mitochondria in pathogenesis of
endothelial dysfunction is due to their role in signaling
cellular responses, among which the production of ROS
[116].
2.2.8. Mitochondrial Monoaminooxidase and Production
of ROS. Among the sources of mitochondrial ROS, the
monoamine oxidase (MAO) family, located to the outermito-
chondrial membrane, causing the oxidative deamination of
catecholamines, results in hydrogen peroxide (H
2
O
2
) forma-
tion [117]. Accordingly, experimental data in literature indi-
cate an increase in H
2
O
2
cardiac production after the sympa-
thomimetic drug amphetamine administration [118]. In this
regard a recent in vitro study has demonstrated in human
pulmonary EC [119] exposed to cocaine a significant increase
in H
2
O
2
production; due to the modulating action of H
2
O
2
on endothelium functions such as endothelium-dependent
vasorelaxation, apoptosis, and remodeling [120] it may be
argued that cocaine-induced increase in catecholamines and
in the consequent MAO-mediated H
2
O
2
production in
endothelial mitochondria could further enhance endothelial
dysfunction, contributing to cocaine toxic effects on vascular
district.
An important contribution to OS may derive from the
process, namely, ROS-induced ROS release (RIRR) [120]: this
process makes a significant amplification to ROS production
[121]. Briefly, OS in themitochondriamay trigger the opening
of mitochondrial transition pore that leads to a further
increase in ROS generation. RIRR phenomena have been
recognized in both physiological (promoting an elevation in
the cell tolerance to OS, until the destruction of impaired-
function mitochondria) [122] and pathological conditions
such as cardiac ischemia-reperfusion [123] associated with
acute myocardial infarction.
2.2.9. ROS Production by Mitochondrial Nox4. Another pos-
sible source of ROS in endothelial mitochondria is Nox4
[124], generating a higher hydrogen peroxide to superoxide
ratio than Nox1 and Nox2. Nox4 involvement in endothelial
cells process and in responses to hypoxia and OS is well
recognized [125]; moreover it has been demonstrated that
the expression or activity of Nox4 is increased in response
to the proinflammatory mediators TNF-𝛼 [126]. While a
cocaine-induced increase in Nox has been demonstrated in
cardiac tissue [64], to date no data in literature are present
on the effects of cocaine on Nox at endothelial level. An
indirect effect of cocaine activation of Nox may derive from
the cocaine induction of the TNF-𝛼 expression, observed in
bovine aortic endothelial cells [127].Moreover a Nox increase
and the consequent endothelial superoxide production were
also found in bovine aortic endothelial cells exposed to
oscillatory shear stress [112].
3. Cocaine Hepatotoxicity
Cocaine abuse is known to induce acute [128–132] and
chronic [130, 131, 133] liver toxicity. Clinical manifestations
of cocaine-induced hepatic damage range from elevation of
liver enzyme levels in chronic users [131, 133, 134] to acute liver
failure associated with hepatitis [128], to fulminant liver fail-
ure associatedwith acute rhabdomyolysis [132] or thrombotic
microangiopathy [128]. Histopathological examination has
shownmidzonal [132] and periportal [130] necrosis, as well as
steatosis in the surviving hepatocytes [131]. The involvement
of OS in cocaine liver toxicity has been reviewed recently
[135, 136].
In vivo animal studies suggest the involvement of cocaine
metabolites in the genesis of hepatotoxicity. Experiments
conducted in rats [137] and mice [138, 139] have shown
that cocaine-induced hepatotoxicity is at least partly depen-
dent on cocaine N-demethylated metabolites norcocaine
(NCOC), and N-hydroxynorcocaine (N-OH-NCOC) and
norcocaine nitroxide (NCOC-NO
∙
) [139, 140]. Inhibition of
cytochrome P-450 (CYP450) mediated activation of cocaine
metabolism produced a significant inhibition of hepatotoxic-
ity in mice in vivo [138] and ex vivo in liver microsomes [141],
while in vivo induction of CYP450 activity enhanced the
cocaine hepatotoxicity [142]. Studies in mice demonstrated
that cocaine reduces GSH levels in the liver [143, 144] and that
depletion of intracellular GSH concentrations exacerbated
cocaine hepatotoxicity [144]. Finally, it has been shown
that pretreatment with the GSH precursor NAC exerted a
protective effect against cocaine hepatotoxicity in mice [145],
while pretreatment with endotoxin lipopolysaccharide (LPS)
led inKuppfer cells to the formation ofNOwhich exacerbated
cocaine toxicity [146].
Given that the synthesis of both NCOC-NO
∙
and GSH
requires the presence of the cofactor NADPH, it has been
hypothesized that a decrease in hepatocytes NADPH content
and consequent impairment of antioxidant system may con-
tribute to enhance OS [147].
The ability of cocaine to deplete intracellular GSH may
also depend on the effects of its N-oxidative metabolites on
themitochondrial function of the hepatocytes. In vivo studies
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in rats [148, 149] have shown that these metabolites can
decrease GSH levels and membrane potential and increase
ROS production in the mitochondria [9]. Mitochondrial
generation of ROS has been shown also in isolated mouse
liver mitochondria treated with NCOC, N-OH-NCOC, and
NCOC-NO
∙
but not with cocaine [150], confirming the
fundamental role of the N-oxidative metabolites of cocaine
in OS-mediated hepatotoxicity.
Ex vivo and in vitro studies have confirmed the in vivo
data. Cocaine-induced GSH depletion and GSSG production
were observed in cultures of mouse and, to a lesser extent,
in rat cocaine-treated hepatocytes [151, 152] with mouse
being more sensitive to cocaine hepatotoxicity, as observed
in cultured liver slices from different species [153]. In primary
cultures of rat hepatocytes treated with the CYP-450 inducer
phenobarbital, it has been observed that cocaine-induced
alteration in the thiol redox equilibrium may be crucial for
the development of hepatocyte toxicity and consequent LDH
release [154].Moreover cocaine-treated hepatocytes had been
associated with decrease in catalase and Mn-SOD [155].
Further confirmation of implication of OS is derived from rat
hepatocyte model of cocaine cytotoxicity in which a partial
prevention of cytotoxicity byNAC [156] and by deferoxamine
(a ferric iron chelator) was observed [152, 156].
In summary, human and experimental data provide
evidence of direct toxic effects of cocaine on the hepatocytes.
This hepatotoxicity appears to be dependent mainly on N-
oxidative metabolites of cocaine. Impairment of the antiox-
idant system as depletion of intracellular and mitochondrial
GSH also contributes to cocaine hepatotoxicity.
4. Potential Therapeutic Effects of OS
Modulators in Cocaine Abuse
Antioxidants or modulators of OS as they are often referred
to due to their possible prooxidant activity can be classified in
low (LMW) and high (HMW) molecular weight and further
subdivided into endogenous or exogenous. The exogenous
ones can be natural or synthetic [2]. Several evidences
indicate that some of these compounds could have beneficial
effects on cocaine-induced toxic effects.
4.1. NAC. NAC has been used for many years in the treat-
ment of acute paracetamol intoxication, as a mucolytic for
chronic obstructive pulmonary disease and as a protec-
tant in contrast-induced nephropathy. NAC can scavenge
directly ROS and particularly the hydroxyl radical ∙OH and
hypochlorous acid but due to its high first pass metabolism
and low bioavailability acts mainly as a precursor of GSH
in many organs, including the liver [145] and the brain
[157]. Asmentioned before,mice pretreatment withNAChad
a protective effect against cocaine-mediated hepatotoxicity
[146]. Importantly, NAC treatments appear to be safe and
tolerable both in preclinical and in clinical studies [158, 159].
GSH is a very important endogenous antioxidant in the
brain and it has been known for a long time that its level
decreases in neuropsychiatric disorders such as depression,
schizophrenia, and bipolar disorder [160] and is currently
considered a promising drug for these pathological condi-
tions [158, 160]. A recent double-blind placebo-controlled
trial failed to demonstrate that NAC reduces cocaine use in
cocaine-dependent subjects but showed some evidence that it
can prevent relapse in individuals who had already achieved
abstinence from cocaine [161]. Thus NAC may be useful as
a relapse prevention agent in abstinent cocaine-dependent
subjects [161].
The mechanism of action of NAC in the aforementioned
conditions is complex and not completely elucidated. The
main activities contributing to its efficacy seem to be related
to (i) its capability of providing cysteine which is the lim-
iting amino acid in GSH production; (ii) the exchange of
extracellular cysteine provided by NAC with intracellular
glutamate by the cysteine/glutamate transporter causing the
activation of presynaptic mGluR2/3 receptors which inhibit
glutamatergic neurotransmission and excitotoxicity [162,
163]; (iii) direct antioxidant activity related to its capability
of scavenging radicals such as hydroxyl and peroxynitrite
[164]; (iv) induction of the expression of antioxidant enzymes
through the nuclear E2-related factor (Nrf2)/ARE system
[165]. It is of note that the Nrf2 pathway represents a promis-
ing therapeutic approach to restore the redox balance in the
CNS and in other organs and that only a few Nrf2-activating
compounds have been tested in a clinical setting until now
[166].
4.2. SOD Mimetics. SOD is a very important antioxidant
enzyme in mammals existing in three different physiological
forms: MnSOD in the mitochondrial matrix, CuZnSOD in
the cytoplasm, and CuZnSOD in extracellular fluids [167].
Given the central role of the superoxide radical in oxidative
pathological phenomena, different drugs with SOD activity
were developed [168].
An infusible formof humanmanganese SOD (rMn-SOD)
as new therapeutic option capable of crossing cell membranes
was recently proposed for dilated cardiomyopathy caused by
cocaine [20].
4.3. Nitroxides andNitrones. Most antioxidants acting as spin
traps have a nitroxide or nitrone nucleus.
Nitroxides are nonmetal catalytic antioxidants. One of
the most common is Tempol (4-hydroxy-2,2,6,6-tetram-
ethylpiperidine-N-oxyl) with SOD and catalase enzymatic
activities which can be administered orally and can cross
biological membranes and react with ROS intracellularly and
within mitochondria [169].
Nitrones are potent antioxidants capable of forming
stable nitroxyl radicals when reacting with oxygen radi-
cals. Several nitrones, including 𝛼-phenyl-tert-butylnitrone
(PBN), have been shown to have neuroprotective properties
in experimental animal models of stroke, Parkinson’s and
Alzheimer’s disease [170], as well as in preclinical models
of CNS injury [171]. Treatment with Tempol can attenuate
OS in the prefrontal cortex and in the nucleus accumbens
[172] and inhibited cocaine self-administration in vivo in rats,
suggesting that reinforcing effects of cocaine are mediated, at
least in part, by ROS [173].
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To the best of our knowledge, no data are present in
literature on efficacy of nitroxides and nitrones on cocaine-
induced cardiac or hepatic injury.
4.4. Nox Inhibitors. As mentioned above, Nox are among
the best characterized sources of superoxide and the pre-
dominant ROS producing enzymes in the vascular smooth
muscle cells, in the myocardium, and in blood vessels [174].
Hypertension, atherosclerosis, hyperlipidemia, and diabetes
are associated with endothelial dysfunction probably medi-
ated by Nox driven production of ROS [175]. Compared to
radical scavengers, Nox inhibitors could be more effective
because they are able to block the formation of ROS at the
source [176].
Several Nox inhibitors are currently available, includ-
ing apocynin, which is an orally active natural compound
obtained from the roots of Picrorhiza kurroa capable of
inhibiting Nox activation probably by preventing the assem-
bly of Nox2 with p47phox [177, 178].
Importantly it was reported that apocynin can prevent
cocaine-induced myocardial damage in rats [64] providing a
good evidence for the therapeutic potential of Nox inhibitors
in the treatment of cocaine cardiotoxicity [179].
4.5. XO Inhibitors. Allopurinol is a well-known inhibitor of
XO used for decades for the treatment of gout [180]. It can
prevent OS by inhibiting XO and also by scavenging directly
hydroxyl free radicals.
Clinical studies showed that allopurinol has beneficial
effects in chronic kidney disease patients [181]. XO inhibition
by allopurinol (or the active metabolite oxypurinol) could
be beneficial in hyperuricemic patients with congestive heart
failure [182]. Unfortunately, allopurinol is not devoid of side
effects such as severe skin reactions and renal impairment
[182].
Allopurinol and 1,3-dimethylthiourea, a scavenger of
hydroxyl radical, produced a potent inhibition of hepatotox-
icity induced by cocaine in adult male mice [183].
Apocynin or allopurinol prevented cocaine-induced car-
diac alteration by restoration of cardiac output, stroke vol-
ume, and fractional shortening, associated with a reduction
of the myocardial production of superoxide anions and an
enhancement of catalase activity [55] suggesting thatNADPH
andXO can act synergically to formmyocardial ROS and that
their inhibition could prevent the onset and progression of
cocaine-induced left ventricular dysfunction [55].
4.6. Mitochondriotropic Antioxidants. Cationic triphenyl-
phosphonium (TPP) derivatives such as MitoQ have high
affinity for the inner mitochondrial membrane that is neg-
atively charged. They can cross the blood-brain barrier even
if the uptake in the brain appears less than for other organs
[184]; TPP compounds can be administered orally and did
not raise safety concerns so far [184]. MitoQ was protective
in a large number of cell models of mitochondrial OS and
has been shown to be well tolerated, orally active, and safe
in humans [185].
Cocaine can be toxic formitochondria, causing formation
of ROS, impaired electron transfer, suppression of ATP
production, membrane permeabilization with release of
cytochrome C, and subsequent cell death: MitoQ can prevent
these abnormalities protecting against cardiac dysfunction
[67].
Preparation of small cell-permeable peptides (SS-
peptides) which accumulate in the mitochondria and bind to
the inner membrane thanks to the presence of basic amino
acids positively charged at physiological pH had shown to
protect mitochondria against oxidative damage [185, 186].
The use of these peptides to deliver antioxidant molecules
into mitochondria and provide protection against cocaine
induced OS has been proposed [187].
4.7. Deferoxamine. NAC and deferoxamine (DFO, an iron
chelating agent that prevents ROS generation by inhibit-
ing the Fenton reaction) protected rat hepatocytes in cul-
ture against the OS induced by cocaine, confirming the
involvement of oxygen radicals in cocaine-induced necro-
sis/apoptosis [188]: hepatocytes were preincubated for 24 h
either in the presence or in the absence of NAC or DFO
and exposed for another 24 h to increasing concentrations of
cocaine together with NAC or DFO. Pretreatment with defer-
oxamine complex with iron ion (III), aminoguanidine, and
N-methyl-d-glucamine dithiocarbamate complex with iron
ion (II) produced a marked inhibition of the hepatotoxicity
induced by a single administration of cocaine, as indicated
by histopathological examination, alanine aminotransferase
activity, and nitrite/nitrate levels [183].
4.8. Selenium. In rats, pretreatment for 4 weeks with sele-
nium reversed both the OS and the contractile dysfunction
induced by repeated (7 days) cocaine administration in rats
[189]: cardiac function was evaluated by cardiac index and
left ventricular fractional shortening measured by echocar-
diography.
4.9. Minocycline. Minocycline, a second generation tetracy-
cline, has been found in rats to prevent cardiac myocyte
death (associated with an increase in OS evidenced by
low GSH/GSSG ratio and increased levels of 4-hydroxy-2-
nonenal) induced by prenatal cocaine exposure [190].
4.10. Auranofin. Pretreatment ofmice with auranofin (a well-
known disease-modifying gold compound used for rheuma-
toid arthritis recently proposed also for other therapeutic
applications) [191] showed an interesting protective effect
against hepatic injury caused by cocaine by inducing over-
expression of heme oxygenase-1 (HO-1), an important OS
marker responsible for heme degradation [192]. Unfortu-
nately, auranofin is not devoid of toxic effects [193] but this
result indicates that it could be worthwhile to search for less
toxic inhibitors of HO-1 to reduce hepatic injury induced by
cocaine.
4.11. Amiodarone. Amiodarone is a class III antiarrhythmic
drug used in heart failure and postischemic heart capable
of protecting cardiac myocytes against OS [194]. However,
amiodarone pretreatment did not affect the seizure incidence
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or mortality in mice treated with high doses of cocaine [195].
The efficacy of amiodarone in the treatment of cocaine-
induced dysrhythmias is still undefined [196] and further
studies should be performed on this and other antiarrhyth-
mic drugs.
4.12. Trolox. Trolox, a hydrophilic analog of vitamin E with
well-known antioxidant properties [197], was found to reduce
the production of ROS induced by exposure to cocaine and
the neurotoxic effect of the HIV-1 transactivating protein Tat
[198].
5. Conclusion
In the present paper, several studies were reported demon-
strating the important role of OS in the activity and toxicity
of cocaine with special attention to its cardiovascular and
hepatic effects. Several evidences were reported showing the
potential beneficial effects of antioxidants or modulators
of OS (as they are referred to considering their possible
prooxidant effects in certain conditions) even if it should be
kept in mind that, like in the case of NAC, their mechanism
of action, which is often complex and not always fully
elucidated, is not only related to their antioxidant activity.
Unfortunately, for most of these modulators of OS the
preclinical and clinical studies are limited and do not allow
drawing definitive conclusions on their efficacy in relation to
cocaine toxicity. Even in the case ofNAC limited clinical trials
were performed in cocaine users and the biomarkers of OS
were not considered with sufficient attention.
Other studies should then be performed also considering
the difficulty to demonstrate the clinical efficacy of modu-
lators of OS. In fact, several clinical trials on antioxidants
in pathological events such as neurodegenerative, cardio-
vascular, or pulmonary diseases, conditions associated with
ischemia and reperfusion injury, chronic kidney disease, or
psychiatric disorders failed in the last few years for different
possible reasons including [1, 2]:
(1) In physiological conditions, OS is controlled by
a complex mixture of endogenous and exogenous
antioxidants (lipophylic or hydrophilic, enzymatic or
nonenzymatic) and when used therapeutically one
single antioxidantmay not be sufficient.The challenge
is then to design trials with the right mixtures of
substances at the right doses.
(2) Certain conditions probably require the delivery of
higher amounts of antioxidants to specific organs or
tissues or organelles such as the mitochondria.
(3) The dose and/or duration and/or regimen and/or
timing of the treatment should be appropriate.
(4) Some antioxidants may have prophylactic activity but
not be very effective after the onset of the condition. If
the stage of the disease is too advanced, patients will
not probably receive benefit from the therapy.
(5) Most clinical trials were performed without a proper
selection of the patients based on validated biomark-
ers of oxidative stress. Furthermore, whole body OS
markers may not be appropriate for specific diseases
in which OS involves specific tissues or organs or
organelles.
(6) Some antioxidants can act as prooxidants in certain
conditions or have adverse side effects.
In conclusion the effect of modulators of OS on the
activity and toxicity of cocaine should be further studied in
order to develop new drugs useful for the treatment of OS-
mediated cocaine toxic effects.
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